AMO makes a move on B&L

Article

Advanced Medical Optics (AMO) has submitted a proposal to acquire Bausch & Lomb for $75 per share in cash and AMO stock.

Advanced Medical Optics (AMO) has submitted a proposal to acquire Bausch & Lomb for $75 per share in cash and AMO stock.

Bausch & Lomb has already entered into a merger agreement process with the private equity firm Warburg Pincus, valued at $4.5 billion. Under the terms of the agreement, Bausch & Lomb was permitted a 50 day period to solicit superior proposals. However, if a better agreement was reached, they are obligated to pay a break-up fee of $40 million to Warburg Pincus.

The AMO proposal values Bausch & Lomb at approximately $4.3 billion in equity value.

In a letter issued on 24 July, however, Bausch & Lomb said it was likely to reject AMO's takeover bid unless AMO could provide evidence that its shareholders will approve the deal.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.